Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGI-101H in advanced melanoma
NCT00716495Phase 2Terminated
- Sponsor
- AGIRx Ltd.
- Start
- Jun 2008
- Primary completion
- Dec 2009
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of AGI-101H vaccine in melanoma, sponsored by AGIRx Ltd.. Started Jun 2008; status: terminated.
02
Drugs
AGI-101H vaccine
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00716495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00716495.